Buprenorphine Pharmacology Related to Addiction Treatment - 18 - Full Text View

Buprenorphine Pharmacology Related to Addiction Treatment - 18

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) University of Vermont
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000236

Purpose

The purpose of this study is to examine the interactions between buprenorphine and naltrexone, and to assess how they may directly impact the clinical issues involving: transferring patients from buprenorphine to naltrexone, developing a non-abusable form of buprenorphine, and enhancing patient acceptability of naltrexone.

Condition	Intervention	Phase
Opioid-Related Disorders	Drug: Buprenorphine/naloxone	Phase II

Drug Information available for:

Naloxone Naloxone hydrochloride Buprenorphine Buprenorphine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Official Title:	Buprenorphine Pharmacology Related to Addiction Treatment

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Drug use
Opioid agonist effects
Opiate withdrawal
Psychological changes in: pupil diameter, blood pressure, heart rate, respiration

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000236

Locations


United States, Vermont
	Treatment Research Center
	Burlington, Vermont, United States, 05401

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Vermont

Investigators


Principal Investigator:	Warren Bickel, Ph.D.	University of Vermont

More Information

Study ID Numbers:	NIDA-06969-18, R01-06969-18
First Received:	September 20, 1999
Last Updated:	August 16, 2005
ClinicalTrials.gov Identifier:	NCT00000236
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Buprenorphine

Behavior, Addictive

Mental Disorders

Substance-Related Disorders

Disorders of Environmental Origin

Opioid-Related Disorders

Naloxone

Additional relevant MeSH terms:

Sensory System Agents

Therapeutic Uses

Narcotic Antagonists

Physiological Effects of Drugs

Central Nervous System Depressants

Narcotics

Peripheral Nervous System Agents

Analgesics

Central Nervous System Agents

Pharmacologic Actions

Analgesics, Opioid

ClinicalTrials.gov processed this record on December 03, 2008